Cashu
Legal Action Against REGENXBIO's Dr. Pakola Highlights Gene Therapy Safety Concerns
about 10 hours ago
Stocks
Health Care
rgnx
Regenxbio
NASDAQ: RGNX
-0.10 (-1.16%)
8.53
USD
At close at Apr 03, 17:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
431.81M
Dividend Yield
0.00%
P/E Ratio
-2.23
EPS
-4.60
Revenue
83.33M
Avg. Volume
553.07K
About
What does RGNX do?
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.